Gene
MAP2K1
MAP2K1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (28), Actionable biomarkers (15), Trial mentions (45), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention MAP2K1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 5 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 3 of 8,738 | 0.03% | not measured | |
| 2025 | 4 of 8,875 | 0.05% | not measured | |
| 2024 | 5 of 8,597 | 0.06% | not measured | |
| 2023 | 5 of 8,275 | 0.06% | 23 of 11,460 | 0.20% |
| 2022 | 2 of 8,285 | 0.02% | 19 of 13,598 | 0.14% |
| 2021 | 4 of 8,692 | 0.05% | 40 of 15,045 | 0.27% |
| 2020 | 8 of 7,640 | 0.10% | 23 of 14,459 | 0.16% |
| 2019 | 3 of 7,300 | 0.04% | 29 of 12,159 | 0.24% |
| 2018 | 0 of 6,927 | 0.00% | 40 of 11,854 | 0.34% |
| 2017 | 3 of 6,558 | 0.05% | 28 of 11,595 | 0.24% |
Showing 10 of 37 years.
Assay-provider ledger (28)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 1 | September 01, 2025 |
| ROCHE DIAGNOSTICS | Context dependent | Clinical validationAnalytical validation | 1 | September 01, 2025 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validationAnalytical validation | 3 | September 01, 2025 |
| OC Medicina de Precisão Oncoclínicas&Co (Oncoclínicas Medicina de Precisão, OCPM) | Diagnostic provider | Clinical validationAnalytical validation | 1 | July 26, 2025 |
| PlexBio (Taiwan) | Diagnostic provider | Clinical validationAnalytical validation | 1 | July 26, 2025 |
Showing 5 of 28 assay-provider companies.
Actionable biomarkers (15)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| MAP2K1 (K57T) | Trametinib | response-associated | colorectal adenocarcinoma | Cancer Genome Interpreter |
| MAP2K1 (K57T) | PANITUMUMAB | response-associated | colorectal adenocarcinoma | Cancer Genome Interpreter |
| MAP2K1 oncogenic mutation | Egfr Mab Inhibitors | responsive | colorectal adenocarcinoma | Cancer Genome Interpreter |
| MAP2K1 (P124) | Erk Inhibitors | response-associated | cutaneous melanoma | Cancer Genome Interpreter |
| MAP2K1 (Q56P,P124S,P124L;C121S) | Braf Inhibitors | responsive | cutaneous melanoma | Cancer Genome Interpreter |
Showing 5 of 15 actionable-biomarker assertions.
Trial mentions (45)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT05997602 | Trial eligibility (AACT) |
| NCT05221320 | Trial eligibility (AACT) |
| NCT07004075 | Trial eligibility (AACT) |
| NCT06553365 | Trial eligibility (AACT) |
| NCT04286360 | Trial eligibility (AACT) |
Showing 5 of 45 trial mentions.
Target-disease associations (409)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| ACTH-Producing Pituitary Gland Adenoma | cancer or benign tumor | Cancer Gene Census |
| Abnormality of the cardiovascular system | phenotype | Variant curation (ClinVar / EVA) |
| Alstrom syndrome | genetic, familial or congenital disease | Literature (Europe PMC) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Ampulla of Vater Carcinoma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 409 associations.
Vendor sourcing (158)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v4.1.0 dataset. Predicted Consequence/Location: Missense variant. Missense changes are a common disease-causing mec... | View ClinVar record SCV002012326.2 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The MAP2K1 c.11A>G; p.Lys4Arg variant (rs761150136), to our knowledge, is not reported in the medical literature but is reported in ClinVar (Variation ID: 49... | View ClinVar record SCV005875606.1 |
| Academic and Community Cancer Research United | Trial sponsor | Exploratory endpoint in a trialTrial endpoint | Cell Free Tumor Deoxyribonucleic Acid (cfDNA) | View trial NCT03992456 |
| Academic and Community Cancer Research United | Trial sponsor | Mentioned in trial textTrial free-text mention | MAP2K1 | View trial NCT03992456 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.389A>G (p.Y130C) alteration is located in coding exon 3 of the MAP2K1 gene. This alteration results from an A to G substitution at nucleotide position ... | View ClinVar record SCV000740780.4 |
Showing 5 of 158 sourcing records.
Trial-cited literature (345)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition. | Cancer cell | 2026 | 4 |
| Monitoring pembrolizumab response in patients with metastatic non-small cell lung cancer using circulating tumour DNA and circulating tumour cells. | Translational lung cancer research | 2025 | 2 |
| Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial. | Nature medicine | 2024 | 69 |
| Intratumoral administration of the immunologic adjuvant AS01<sub>B</sub> in combination with autologous CD1c (BDCA-1)<sup>+</sup>/CD141 (BDCA-3)<sup>+</sup> myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma. | Journal for immunotherapy of cancer | 2024 | 8 |
| Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study. | BMC cancer | 2024 | 6 |
Showing 5 of 345 papers.
Protein variant mentions (20)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.D67N | 4 | 2008 to 2021 | PMID 33448881, PMID 27142472, PMID 25741868 |
| p.F53L | 1 | 2016 | PMID 26619011 |
| p.F53S | 2 | 2008 to 2018 | PMID 29643386, PMID 18632602 |
| p.G128A | 1 | 2018 | PMID 29758562 |
| p.H119Y | 1 | 2015 | PMID 25741868 |
Showing 5 of 20 variants.
Human sample screening reference (1)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.L177M | TCGA-STAD | Adenomas and Adenocarcinomas; Cystic, Mucinous and Serous Neoplasms; Stomach | 2 | 443 | 0.45% | 0.12% to 1.63% |
Literature-extracted relations (61)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| CETUXIMAB | Chemical | associate |
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial. | 2024 |
| Vitamin K 2 | Chemical | negative_correlate |
Vitamin K2 Suppresses Proliferation and Inflammatory Cytokine Production in Mitogen-Activated Lymphocytes of Atopic Dermatitis Patients through the Inhibition of Mitogen-Activated Protein Kinases. | 2021 |
| Poly IC | Chemical | associate |
Differential Inflammatory-Response Kinetics of Human Keratinocytes upon Cytosolic RNA- and DNA-Fragment Induction. | 2018 |
| SIMVASTATIN | Chemical | associate |
Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. | 2016 |
| ADENOSINE TRIPHOSPHATE | Chemical | associate |
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. | 2014 |
Showing 5 of 61 relation assertions.
Organizations publishing (380)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 34 | 2008 to 2026 |
| The University of Texas System | Academic | 23 | 2011 to 2023 |
| Government of the United States of America | Government | 22 | 2014 to 2023 |
| Dana-Farber Cancer Institute | Other | 18 | 2011 to 2023 |
| University of California System | Academic | 11 | 2011 to 2022 |
Showing 5 of 380 organizations.
Where MAP2K1 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
323 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.